150 related articles for article (PubMed ID: 15811864)
21. Comeback for glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions for saphenous vein bypass grafts: may be for distal protection with filter-based devices?
Niemelä KO
Eur Heart J; 2006 Apr; 27(8):891-2. PubMed ID: 16484318
[No Abstract] [Full Text] [Related]
22. Early and late ischemic complications of PTCA.
Ferguson JJ; Wilson JM
J Invasive Cardiol; 1994; 6 Suppl A():3A-12A, discussion 43A-45A. PubMed ID: 10155092
[No Abstract] [Full Text] [Related]
23. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
Sabatine MS; Hamdalla HN; Mehta SR; Fox KA; Topol EJ; Steinhubl SR; Cannon CP
Am Heart J; 2008 May; 155(5):910-7. PubMed ID: 18440341
[TBL] [Abstract][Full Text] [Related]
24. Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)?
Berger PB; Sketch MH; Califf RM
Circulation; 2004 Mar; 109(9):1079-81. PubMed ID: 15007018
[No Abstract] [Full Text] [Related]
25. Percutaneous coronary intervention versus coronary artery bypass surgery in multivessel disease: a current perspective.
Soran O; Manchanda A; Schueler S
Interact Cardiovasc Thorac Surg; 2009 Jun; 8(6):666-71. PubMed ID: 19307243
[TBL] [Abstract][Full Text] [Related]
26. Surgery, angioplasty, or medical therapy for symptomatic multivessel coronary artery disease: is there an indisputable "winning strategy" from evidence-based clinical trials?
Boden WE
J Am Coll Cardiol; 2004 May; 43(10):1752-4. PubMed ID: 15145094
[No Abstract] [Full Text] [Related]
27. eComment: Costs of percutaneous coronary intervention versus coronary artery bypass surgery.
Almeida RM
Interact Cardiovasc Thorac Surg; 2009 Jun; 8(6):672. PubMed ID: 19443497
[No Abstract] [Full Text] [Related]
28. Overview of systematic reviews on invasive treatment of stable coronary artery disease.
Kuukasjärvi P; Malmivaara A; Halinen M; Hartikainen J; Keto PE; Talvensaari T; Tierala I; Mäkelä M
Int J Technol Assess Health Care; 2006; 22(2):219-34. PubMed ID: 16571198
[TBL] [Abstract][Full Text] [Related]
29. Stenting or surgery: an opportunity to do it right.
Califf RM
J Am Coll Cardiol; 2005 Aug; 46(4):589-91. PubMed ID: 16098420
[No Abstract] [Full Text] [Related]
30. Percutaneous coronary intervention versus coronary-artery bypass grafting.
Edwards JL
N Engl J Med; 2009 Jun; 360(25):2672-3; author reply 2674-5. PubMed ID: 19537314
[No Abstract] [Full Text] [Related]
31. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
32. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
[No Abstract] [Full Text] [Related]
33. GP IIb/IIIa blockade during peripheral artery interventions.
Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients.
Stroupe KT; Morrison DA; Hlatky MA; Barnett PG; Cao L; Lyttle C; Hynes DM; Henderson WG;
Circulation; 2006 Sep; 114(12):1251-7. PubMed ID: 16966588
[TBL] [Abstract][Full Text] [Related]
35. Diabetic multivessel disease: stenting vs. coronary artery bypass grafting.
Bansilal S; Farkouh M; Sharma S; Fuster V
Indian Heart J; 2007; 59(2 Suppl B):B72-82. PubMed ID: 19153439
[No Abstract] [Full Text] [Related]
36. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease.
Javaid A; Steinberg DH; Buch AN; Corso PJ; Boyce SW; Pinto Slottow TL; Roy PK; Hill P; Okabe T; Torguson R; Smith KA; Xue Z; Gevorkian N; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
Circulation; 2007 Sep; 116(11 Suppl):I200-6. PubMed ID: 17846304
[TBL] [Abstract][Full Text] [Related]
37. Drug-eluting stents for interventional revascularization of coronary multivessel disease.
Ong AT; van der Giessen WJ
J Interv Cardiol; 2005 Dec; 18(6):447-53. PubMed ID: 16336425
[TBL] [Abstract][Full Text] [Related]
38. Temporal trends in major angioplasty complications: technical issues and the case for on-site coronary surgery.
Mishra KJ; Sage PR; Philpott AC; Zeitz CJ; Horowitz JD
Intern Med J; 2006 Jul; 36(7):458-61. PubMed ID: 16780454
[TBL] [Abstract][Full Text] [Related]
39. Stenting the coronaries and bypassing the evidence in patients with multivessel coronary artery disease: time to set the record straight.
Zingone B
J Cardiovasc Med (Hagerstown); 2007 May; 8(5):362-70. PubMed ID: 17443104
[No Abstract] [Full Text] [Related]
40. Cardiovascular disease in diabetes.
Malcolm J; Meggison H; Sigal R
Clin Evid; 2002 Dec; (8):541-68. PubMed ID: 12603899
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
